#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15106	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2161	692.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1681	1681	T	841	T,C	770,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15106	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2161	692.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1415	1415	C	871	C	809	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15106	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2161	692.7	0	HET	.	.	.	G1378A	.	1378	1378	G	1609	1609	G	845	G,A	600,199	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26776	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3563	748.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1693	1693	A	891	A	847	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26776	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3563	748.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2327	2327	C	842	C,G	785,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26776	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3563	748.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2401	2401	A	865	A	817	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26776	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3563	748.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2953	2953	C	797	C,G	745,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2168	folP	855	855	100.0	folP.l6.c30.ctg.1	1656	130.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1066	1068	AGC	196;195;194	A;G;C	185;182;180	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5744	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3479	164.1	1	SNP	p	S91F	1	.	.	271	273	TTC	657	659	TTC	199;198;197	T;T;C	186;184;185	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5744	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3479	164.1	1	SNP	p	D95G	1	.	.	283	285	GGC	669	671	GGC	198;194;194	G;G;C	185;183;187	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5744	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3479	164.1	1	SNP	p	G95N	0	.	.	283	285	GGC	669	671	GGC	198;194;194	G;G;C	185;183;187	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1862	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1304	141.7	1	SNP	p	G45D	0	.	.	133	135	GGC	488	490	GGC	214;217;217	G;G;C	204;205;203	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	914	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1171	77.6	0	.	n	.	0	A197.	DEL	197	197	A	684	684	A	209	A	197	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5372	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3056	175.1	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1564	1566	GTC	208;208;208	G;T;C	195;194;194	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5372	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3056	175.1	1	SNP	p	D86N	0	.	.	256	258	GAC	670	672	GAC	206;206;206	G;A;C,G	190;185;188,1	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5372	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3056	175.1	1	SNP	p	R87I	0	.	.	259	261	CGT	673	675	CGT	212;211;211	C;G;T	198;195;195	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5372	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3056	175.1	1	SNP	p	S87R	1	.	.	259	261	CGT	673	675	CGT	212;211;211	C;G;T	198;195;195	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5372	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3056	175.1	1	SNP	p	R87W	0	.	.	259	261	CGT	673	675	CGT	212;211;211	C;G;T	198;195;195	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5372	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3056	175.1	1	SNP	p	S88P	0	.	.	262	264	TCC	676	678	TCC	209;210;210	T;C;C	194;195;197	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4634	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2584	178.1	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1354	1356	TGC	216;211;211	T;G;C,T	200;195;195,2	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4634	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2584	178.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1564	1566	GGC	246;244;244	G;G;C	232;233;230	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4122	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2358	173.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1263	1265	GCA	251;252;252	G;C;A	230;230;234	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4122	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2358	173.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1266	1268	ATC	252;252;254	A;T;C	232;229;230	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4122	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2358	173.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1278	1280	GTG	252;252;251	G;T;G	229;227;228	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4122	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2358	173.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1278	1280	GTG	252;252;251	G;T;G	229;227;228	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4122	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2358	173.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1782	1784	ACC	192;189;190	A;C;C	173;177;176	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4122	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2358	173.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1836	1838	GCG	193;193;196	G;C;G,T	169;156;165,1	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4122	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2358	173.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1836	1838	GCG	193;193;196	G;C;G,T	169;156;165,1	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4122	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2358	173.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1959	1961	GGC	179;177;176	G;G;C	161;156;160	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4122	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2358	173.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1968	1970	GGC	177;176;177	G;G;C	160;156;158	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4122	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2358	173.8	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1986	1988	TCG	172;173;169	T,G,C;C;G	119,9,1;137;143	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6084	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3226	187.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1632	1634	CCG	212;215;214	C;C;G	185;193;185	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2558	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1739	145.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	545	545	C	182	C	168	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	366	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1612	22.6	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1138	1140	AAT	17;17;17	A;A;T	17;17;17	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	366	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1612	22.6	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1141	1143	AAT	17;17;18	A;A;T	17;16;18	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	366	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1612	22.6	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1153	1155	GTT	21;21;21	G;T;T	21;21;21	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	366	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1612	22.6	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1165	1167	GCA	21;21;21	G;C;A	20;20;20	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	366	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1612	22.6	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1188	1190	GTA	24;24;23	G;T;A	24;24;23	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	366	porB1a	984	363	90.19	porB1a.l15.c4.ctg.1	1612	22.6	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1200	1200	G	33	G	32	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	3056	porB1b	1041	1041	96.64	porB1b.l15.c4.ctg.1	1463	206.7	0	.	p	.	0	T87A	NONSYN	259	261	ACT	543	545	GCT	230;229;228	G;C;T	210;210;202	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	3056	porB1b	1041	1041	96.64	porB1b.l15.c4.ctg.1	1463	206.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	684	686	GAT	241;244;247	G,A;A;T	227,1;231;234	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	3056	porB1b	1041	1041	96.64	porB1b.l15.c4.ctg.1	1463	206.7	0	.	p	.	0	K143E	NONSYN	427	429	AAA	711	713	GAA	245;247;251	G,A,C;A;A	225,1,1;232;236	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	3056	porB1b	1041	1041	96.64	porB1b.l15.c4.ctg.1	1463	206.7	0	.	p	.	0	N189G	NONSYN	565	567	AAC	849	851	GGC	228;226;225	G;G;C	213;209;205	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	3056	porB1b	1041	1041	96.64	porB1b.l15.c4.ctg.1	1463	206.7	0	.	p	.	0	K207fs	FSHIFT	619	619	A	903	903	A	208	A	201	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	3056	porB1b	1041	1041	96.64	porB1b.l15.c4.ctg.1	1463	206.7	1	SNP	p	G120K	1	.	.	358	360	AAG	642	644	AAG	228;225;222	A;A;G	218;216;214	porB1b.WHO_O_01976:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	3056	porB1b	1041	1041	96.64	porB1b.l15.c4.ctg.1	1463	206.7	1	SNP	p	D121N	0	.	.	361	363	GAC	645	647	GAC	222;223;226	G;A;C,A	212;212;210,1	porB1b.WHO_O_01976:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	3056	porB1b	1041	1041	96.64	porB1b.l15.c4.ctg.1	1463	206.7	1	SNP	p	A121D	1	.	.	361	363	GAC	645	647	GAC	222;223;226	G;A;C,A	212;212;210,1	porB1b.WHO_O_01976:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11500	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4854	235.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1916	1918	AAT	308;310;311	A;A;T	283;282;282	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1236	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1061	115.2	1	SNP	p	V57M	1	.	.	169	171	ATG	444	446	ATG	257;257;260	A,G;T;G,T	240,1;240;241,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
